annual cash & cash equivalents:
$5.49B-$352.00M(-6.03%)Summary
- As of today (May 29, 2025), AZN annual cash & cash equivalents is $5.49 billion, with the most recent change of -$352.00 million (-6.03%) on December 31, 2024.
- During the last 3 years, AZN annual cash & cash equivalents has fallen by -$841.00 million (-13.29%).
- AZN annual cash & cash equivalents is now -48.70% below its all-time high of $10.70 billion, reached on December 31, 2010.
Performance
AZN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$5.23B(NaN%)Summary
- As of today (May 29, 2025), AZN quarterly cash & cash equivalents is $5.23 billion
- Over the past year, AZN quarterly cash & cash equivalents has dropped by -$2.61 billion (-33.30%).
- AZN quarterly cash & cash equivalents is now -66.40% below its all-time high of $15.57 billion, reached on June 30, 2021.
Performance
AZN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AZN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.0% | -33.3% |
| 3 y3 years | -13.3% | -9.2% |
| 5 y5 years | +2.2% | +53.2% |
AZN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -13.3% | at low | -33.3% | +17.3% |
| 5 y | 5-year | -29.9% | +2.2% | -66.4% | +53.2% |
| alltime | all time | -48.7% | +4146.4% | -66.4% | >+9999.0% |
AZN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $5.23B(+9.0%) |
| Dec 2024 | $5.49B(-6.0%) | - |
| Sep 2024 | - | $4.80B(-30.6%) |
| Jun 2024 | - | $6.92B(-11.8%) |
| Mar 2024 | - | $7.84B(+61.0%) |
| Dec 2023 | $5.84B(-5.3%) | - |
| Sep 2023 | - | $4.87B(-14.0%) |
| Jun 2023 | - | $5.66B(-9.1%) |
| Mar 2023 | - | $6.23B(+1.1%) |
| Dec 2022 | $6.17B(-2.6%) | $6.17B(+38.3%) |
| Sep 2022 | - | $4.46B(-7.5%) |
| Jun 2022 | - | $4.82B(-16.4%) |
| Mar 2022 | - | $5.76B(-9.0%) |
| Dec 2021 | $6.33B(-19.2%) | $6.33B(-10.4%) |
| Sep 2021 | - | $7.07B(-54.6%) |
| Jun 2021 | - | $15.57B(+103.9%) |
| Mar 2021 | - | $7.64B(-2.5%) |
| Dec 2020 | $7.83B(+45.9%) | $7.83B(-3.0%) |
| Sep 2020 | - | $8.07B(+42.3%) |
| Jun 2020 | - | $5.67B(+66.2%) |
| Mar 2020 | - | $3.41B(-36.4%) |
| Dec 2019 | $5.37B(+13.1%) | $5.37B(+35.3%) |
| Sep 2019 | - | $3.97B(-26.9%) |
| Jun 2019 | - | $5.43B(+31.2%) |
| Mar 2019 | - | $4.14B(-12.8%) |
| Dec 2018 | $4.75B(+42.7%) | $4.75B(+38.7%) |
| Sep 2018 | - | $3.42B(+14.8%) |
| Jun 2018 | - | $2.98B(-0.9%) |
| Mar 2018 | - | $3.00B(-9.6%) |
| Dec 2017 | $3.32B(-32.5%) | $3.32B(-17.6%) |
| Sep 2017 | - | $4.04B(-23.0%) |
| Jun 2017 | - | $5.24B(+67.4%) |
| Mar 2017 | - | $3.13B(-36.5%) |
| Dec 2016 | $4.93B(-19.6%) | $4.93B(+59.4%) |
| Sep 2016 | - | $3.09B(-21.1%) |
| Jun 2016 | - | $3.92B(+14.2%) |
| Mar 2016 | - | $3.43B(-44.1%) |
| Dec 2015 | $6.13B(-1.9%) | $6.13B(+50.2%) |
| Sep 2015 | - | $4.08B(+2.9%) |
| Jun 2015 | - | $3.97B(+24.3%) |
| Mar 2015 | - | $3.19B(-48.9%) |
| Dec 2014 | $6.25B(-31.3%) | $6.25B(+21.4%) |
| Sep 2014 | - | $5.15B(+3.8%) |
| Jun 2014 | - | $4.96B(+13.2%) |
| Mar 2014 | - | $4.38B(-51.9%) |
| Dec 2013 | $9.10B(+22.9%) | $9.10B(+22.1%) |
| Sep 2013 | - | $7.45B(-9.7%) |
| Jun 2013 | - | $8.25B(+14.1%) |
| Mar 2013 | - | $7.23B(-2.2%) |
| Dec 2012 | $7.40B(+5.3%) | $7.40B(+23.0%) |
| Sep 2012 | - | $6.02B(-21.3%) |
| Jun 2012 | - | $7.64B(+20.7%) |
| Mar 2012 | - | $6.33B(-9.9%) |
| Dec 2011 | $7.03B(-34.3%) | $7.03B(-28.7%) |
| Sep 2011 | - | $9.86B(+2.6%) |
| Jun 2011 | - | $9.61B(+0.3%) |
| Mar 2011 | - | $9.58B(-10.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2010 | $10.70B(+7.9%) | $10.70B(+6.9%) |
| Sep 2010 | - | $10.01B(+10.1%) |
| Jun 2010 | - | $9.09B(+23.4%) |
| Mar 2010 | - | $7.37B(-25.7%) |
| Dec 2009 | $9.92B(+131.4%) | $9.92B(+27.3%) |
| Sep 2009 | - | $7.79B(+8.3%) |
| Jun 2009 | - | $7.20B(+62.0%) |
| Mar 2009 | - | $4.44B(+3.6%) |
| Dec 2008 | $4.29B(-26.9%) | $4.29B(+21.0%) |
| Sep 2008 | - | $3.54B(-18.4%) |
| Jun 2008 | - | $4.34B(+48.6%) |
| Mar 2008 | - | $2.92B(-50.2%) |
| Dec 2007 | $5.87B(-17.4%) | $5.87B(+71.1%) |
| Sep 2007 | - | $3.43B(-30.8%) |
| Jun 2007 | - | $4.95B(-11.1%) |
| Mar 2007 | - | $5.57B(-21.6%) |
| Dec 2006 | $7.10B(+42.7%) | $7.10B(+23.4%) |
| Sep 2006 | - | $5.76B(-5.3%) |
| Jun 2006 | - | $6.08B(-14.5%) |
| Mar 2006 | - | $7.10B(+42.7%) |
| Dec 2005 | $4.98B(+371.9%) | $4.98B(+13.2%) |
| Sep 2005 | - | $4.40B(-19.3%) |
| Jun 2005 | - | $5.45B(+9.5%) |
| Mar 2005 | - | $4.98B(+371.9%) |
| Dec 2004 | $1.05B(+43.9%) | $1.05B(+3.4%) |
| Sep 2004 | - | $1.02B(-32.0%) |
| Jun 2004 | - | $1.50B(+84.2%) |
| Mar 2004 | - | $814.00M(+11.1%) |
| Dec 2003 | $733.00M(+1.0%) | $733.00M(>+9900.0%) |
| Sep 2003 | - | $0.00(-100.0%) |
| Jun 2003 | - | $4.00B(>+9900.0%) |
| Mar 2003 | - | $0.00(-100.0%) |
| Dec 2002 | $726.00M(+3.0%) | $726.00M(>+9900.0%) |
| Sep 2002 | - | $0.00(-100.0%) |
| Jun 2002 | - | $4.27B(>+9900.0%) |
| Mar 2002 | - | $0.00(-100.0%) |
| Dec 2001 | $705.00M(-31.0%) | $705.00M(>+9900.0%) |
| Sep 2001 | - | $0.00(-100.0%) |
| Jun 2001 | - | $4.26B(>+9900.0%) |
| Mar 2001 | - | $0.00(-100.0%) |
| Dec 2000 | $1.02B(+138.1%) | $1.02B(>+9900.0%) |
| Sep 2000 | - | $0.00(-100.0%) |
| Jun 2000 | - | $2.95B(>+9900.0%) |
| Mar 2000 | - | $0.00(-100.0%) |
| Dec 1999 | $429.00M(-86.3%) | $429.00M(-88.7%) |
| Sep 1999 | - | $3.79B(+88.1%) |
| Jun 1999 | - | $2.02B(-35.8%) |
| Dec 1998 | $3.14B(+526.5%) | $3.14B(+859.6%) |
| Jun 1998 | - | $327.00M(-34.7%) |
| Dec 1997 | $500.89M(+12.9%) | $500.89M(+12.9%) |
| Dec 1996 | $443.54M(+76.1%) | $443.54M(+76.1%) |
| Dec 1995 | $251.87M(-70.6%) | $251.87M(-73.8%) |
| Jun 1995 | - | $961.50M(+12.2%) |
| Dec 1994 | $856.75M(-36.6%) | $856.75M(-36.6%) |
| Dec 1993 | $1.35B(+190.4%) | $1.35B |
| Dec 1992 | $465.62M(-1.6%) | - |
| Dec 1991 | $473.41M(+266.3%) | - |
| Dec 1990 | $129.24M | - |
FAQ
- What is AstraZeneca annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for AstraZeneca?
- What is AstraZeneca annual cash & cash equivalents year-on-year change?
- What is AstraZeneca quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for AstraZeneca?
- What is AstraZeneca quarterly cash & cash equivalents year-on-year change?
What is AstraZeneca annual cash & cash equivalents?
The current annual cash & cash equivalents of AZN is $5.49B
What is the all time high annual cash & cash equivalents for AstraZeneca?
AstraZeneca all-time high annual cash & cash equivalents is $10.70B
What is AstraZeneca annual cash & cash equivalents year-on-year change?
Over the past year, AZN annual cash & cash equivalents has changed by -$352.00M (-6.03%)
What is AstraZeneca quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AZN is $5.23B
What is the all time high quarterly cash & cash equivalents for AstraZeneca?
AstraZeneca all-time high quarterly cash & cash equivalents is $15.57B
What is AstraZeneca quarterly cash & cash equivalents year-on-year change?
Over the past year, AZN quarterly cash & cash equivalents has changed by -$2.61B (-33.30%)